Live Breaking News & Updates on Mutation Testing

Stay updated with breaking news from Mutation testing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

WILMINGTON, Del. (BUSINESS WIRE) Jun 2, 2024 ....

United States , United Kingdom , Chelsea Tressler , Daiichi Sankyo , Brendan Mcevoy , American Society Of Clinical Oncology , World Health Organization , Lungevity Foundation , Lung Ambition Alliance , International Agency For Research On Cancer , Archives Pathology Lab , Single Institution Study , Plenary Session , Clinical Oncology , Annual Meeting , New England Journal , Prescription Information , Patient Information , South America , Rare Diseases , International Agency , Lung Fact , Accessed May , Cancer Biomarkers , Present Status , Clinical Oncology Provisional Opinion ,

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated ...

— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — ....

Hong Kong , United States , Atholl Tweedie , Zhou Yi , Ben Atwell , Single Institution Study , American Cancer Society , Stock Exchange Of Hong Kong , China National Medical Products Administration , Exchange Commission , European Lung Cancer Congress On , European Lung Cancer Congress , National Reimbursement Drug List , World Health Organization , China Limited , International Agency For Research On Cancer , New Drug Application , Lung Cancer , Securities Litigation Reform Act , Stock Exchange , Hong Kong Limited , International Agency , Accessed November , Clinical Oncology Provisional Opinion , Epidermal Growth Factor Receptor , Mutation Testing ,

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients If. ....

Hong Kong , United States , Ben Atwell , Zhou Yi , Atholl Tweedie , China Limited , European Lung Cancer Congress On , American Cancer Society , National Reimbursement Drug List , Stock Exchange Of Hong Kong , European Lung Cancer Congress , International Agency For Research On Cancer , World Health Organization , Exchange Commission , Single Institution Study , China National Medical Products Administration , New Drug Application , Lung Cancer , Securities Litigation Reform Act , Stock Exchange , Hong Kong Limited , International Agency , Clinical Oncology Provisional Opinion , Epidermal Growth Factor Receptor , Mutation Testing , Kinase Inhibitor ,

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

First EGFR inhibitor and targeted treatment to demonstrate progression-free survival benefit in Stage III setting

. ....

United States , United Kingdom , Suresh Ramalingam , Susan Galbraith , Cerner Cancermpact , Daiichi Sankyo , International Agency For Research On Cancer , American Cancer Society , Lung Ambition Alliance , Winship Cancer Institute Of Emory University , Lungevity Foundation , Single Institution Study , World Health Organisation , Executive Director , Winship Cancer Institute , Emory University , Executive Vice President , Prescription Information , Patient Information , South America , Rare Diseases , International Agency , Lung Fact , Accessed February , What Is Lung , Clinical Oncology Provisional Opinion ,

AstraZeneca's Tagrisso plus chemotherapy appoved for lung cancer in the US

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit. ....

United States , Dave Fredrickson , Laurie Ambrose , American Cancer Society , Pathology Lab , Drug Administration , Dana Farber Cancer Institute , National Comprehensive Cancer Network , Lungevity Foundation , National Comprehensive Cancer Network Inc , Priority Review , New England Journal , Executive Vice President , Oncology Business Unit , Lung Cancer , Practical Guidelines , Project Orbis , Non Small Cell , Accessed February , What Is Lung , Cancer Biomarkers , Present Status , Clinical Oncology Provisional Opinion , Epidermal Growth Factor Receptor , Mutation Testing , Kinase Inhibitor ,